Post-Marketing Study of Mirabegron - Long-term Add-on Therapy With Anticholinergics in Patients With Overactive Bladder Under Treatment With Mirabegron
Phase of Trial: Phase IV
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Mirabegron (Primary) ; Imidafenacin; Propiverine; Solifenacin; Tolterodine
- Indications Overactive bladder
- Focus Adverse reactions
- Acronyms MILAI II STUDY
- Sponsors Astellas Pharma
- 04 Oct 2016 Status changed from active, no longer recruiting to completed.
- 08 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 22 Nov 2014 New trial record